Find in Library

708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors

oleh: Jing Wang, Jian Zhang, Jun Zhang, Ning Li, Xiaohua Wu, Elizabeth Lee, Naomi Hunder, Ying Cheng, Debra L Richardson, Erika Hamilton, Lin Wu, Ira Winer, Ian Anderson, Gottfried Konecny, Douglas Orr, Oladapo Yeku, Sandip P Patel, Sharon Ma, Eric Song, Justin A Call, Lian Lu